Corcept Therapeutics
Corcept Therapeutics is a Menlo Park-based biopharmaceutical company that discovers and commercializes selective glucocorticoid receptor antagonists, with two FDA-approved drugs (Korlym for Cushing's syndrome, Lifyorli for platinum-resistant ovarian cancer) and a pipeline spanning endocrinology, oncology, metabolism, and neurology.
- Company typePublic
- Founded1999
- HeadquartersMenlo Park, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Corcept Therapeutics does
Corcept Therapeutics is a Menlo Park, California-based biopharmaceutical company founded in 1999 by Joseph K. Belanoff and Alan F. Schatzberg to develop small-molecule drugs that modulate cortisol activity at the glucocorticoid receptor (GR). The company has built a proprietary library of more than 1,000 selective glucocorticoid receptor antagonists (SGRAs) and runs 30+ ongoing clinical studies spanning endocrinology, oncology, metabolism, and neurology. Its two FDA-approved products are Korlym (mifepristone), the first treatment approved for hypercortisolism/Cushing's syndrome in 2012, and Lifyorli (relacorilant), the first selective GR antagonist approved for any oncology indication after FDA approval in March 2026 for platinum-resistant ovarian cancer in combination with nab-paclitaxel. The pipeline includes relacorilant (Cushing's syndrome NDA resubmitted June 2026 following a December 2025 Complete Response Letter), dazucorilant (Phase 2 ALS data showing an 87% reduction in death risk at two years, Phase 3 planned), and miricorilant (Phase 2 MONARCH in MASH).
The business is organized around specialty pharmaceutical commercialization: Corcept sells its approved drugs through specialty pharmacy partnerships (Onco360 was selected as the national pharmacy partner for Lifyorli) and supports prescribers and patients through the Corcept Cares Patient Advocate Program, medical affairs engagement, and educational platforms. Korlym prescriptions have nearly doubled year-over-year despite authorized generics now representing over 50% of prescriptions and driving a 13% year-over-year average per-tablet price decline. Revenue grew from $675 million in 2024 to $761 million in 2025, with Q1 2026 revenue of $164.9 million and management's 2026 guidance raised to $950 million-$1.05 billion reflecting transition from a single Cushing's syndrome franchise to a multi-product oncology and endocrinology portfolio. The company employs 400+ people and is publicly traded on NASDAQ under the ticker CORT with a market capitalization of approximately $7.45 billion as of late May 2026, up roughly 114% year-to-date following the Lifyorli approval.
Corcept Therapeutics firmographics
Firmographics- Name
- Corcept Therapeutics
- Legal name
- Corcept Therapeutics Incorporated
- Website
- https://corcept.com
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Corcept Therapeutics is a Menlo Park-based biopharmaceutical company that discovers and commercializes selective glucocorticoid receptor antagonists, with two FDA-approved drugs (Korlym for Cushing's syndrome, Lifyorli for platinum-resistant ovarian cancer) and a pipeline spanning endocrinology, oncology, metabolism, and neurology.
- Ownership category
- akta.pro rank
Corcept Therapeutics industry classification
Industry- Product category
- Endocrinology / Oncology Specialty Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrine Hypertension & Neuroendocrine Disorders (HLAKADAN)
Keywords
Where Corcept Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Corcept Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
Revenue model
- Product Sales (Korlym and Lifyorli): Corcept generates revenue primarily from the sale of two FDA-approved drugs: Korlym (mifepristone) for Cushing's syndrome, which was the first approved treatment for hypercortisolism (2012), and Lifyorli (relacorilant) for platinum-resistant ovarian cancer (FDA approved March 2026). Revenue is driven by prescription volume, with the company noting pricing pressures from authorized generics now accounting for over 50% of prescriptions causing a 13% year-over-year average price decline per tablet for Korlym. 2025 full-year revenue was $761 million (up 13% from $675 million in 2024). Q1 2026 revenue was $164.9 million.
- Revenue from Cushing's Syndrome Franchise: Strong prescriber growth with prescriptions nearly doubling year-over-year for Korlym, supported by record patient starts. Full-year 2026 guidance set at $950 million to $1.05 billion, reflecting transition from single-product Cushing's syndrome focus toward broader glucocorticoid receptor-targeted oncology and endocrine portfolio.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Korlym (mifepristone) - prescription drug for Cushing's syndrome |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Corcept Therapeutics product offering
Product offeringCore offering
Corcept Therapeutics discovers, develops, and commercializes FDA-approved drugs that regulate the effects of cortisol by modulating the glucocorticoid receptor (GR). The company sells two approved drugs: Korlym (mifepristone), the first FDA-approved treatment for hypercortisolism (Cushing's syndrome) approved in 2012, and Lifyorli (relacorilant), the first selective glucocorticoid receptor antagonist approved (March 2026) for platinum-resistant ovarian cancer in combination with nab-paclitaxel.
Product overview
Corcept Therapeutics is a biopharmaceutical company focused on cortisol modulation therapy with two FDA-approved products and multiple clinical-stage candidates. The company's portfolio consists of Korlym (mifepristone), approved in 2012 as the first treatment for hypercortisolism (Cushing syndrome), and Lifyorli (relacorilant), approved in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer. The company is pursuing additional indications for relacorilant in Cushing's syndrome, has dazucorilant in Phase 2 for ALS, and miricorilant in Phase 2 for MASH, with over 30 ongoing clinical studies across endocrinology, oncology, metabolism, and neurology.
Differentiator
Problem solved
Functional benefit
Products and services
- Korlym (mifepristone) FDA-approved treatment for hypercortisolism (Cushing's syndrome), the first approved treatment for this condition. Mifepristone is a glucocorticoid receptor antagonist that competitively and reversibly binds to the glucocorticoid receptor to modulate cortisol activity. Korlym is sold as 300 mg tablets and faces authorized-generic pricing pressure, with authorized generics now accounting for over 50% of prescriptions.
- Lifyorli (relacorilant) FDA-approved selective glucocorticoid receptor antagonist (SGRA) approved in March 2026 in combination with nab-paclitaxel for treating adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. It is the first FDA-approved selective glucocorticoid receptor antagonist for oncology, included in NCCN Guidelines as a preferred regimen, and is distributed nationally through Onco360 specialty pharmacy.
Quantifiable outcome
- 35% reduction in risk of death (HR: 0.65; p=0.0004) and 30% reduction in risk of disease progression in platinum-resistant ovarian cancer with Lifyorli plus nab-paclitaxel vs nab-paclitaxel alone; median OS 16.0 months vs 11.9 months
- +5 more outcomes
Companies that use Corcept Therapeutics
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Corcept Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Corcept Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Onco360coreOnco360, the largest independent oncology pharmacy in the United States, was selected as the national pharmacy partner for LIFYORLI (relacorilant). Onco360 provides specialized dispensing, clinical support, and patient services for oncology medications, enabling Corcept to reach patients with platinum-resistant ovarian cancer across the country.
Scale indicators10 records
Recent moves6 records
Expansion highlights4 records
Corcept Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Major oncology player with PARP inhibitors (Talzenna) and broad ovarian cancer development programs; competes for platinum-resistant ovarian cancer share.
- Ipsen: Global specialty pharma with Signifor (pasireotide) approved for Cushing's disease. Competes with Korlym and relacorilant in the same Cushing's syndrome specialty channel.
- Novartis: Large pharma with historic presence in Cushing's disease via pasireotide co-development and broader oncology footprint relevant to platinum-resistant ovarian cancer.
- AstraZeneca: Oncology incumbent with Lynparza in ovarian cancer and a broad development pipeline; competes for the same platinum-resistant ovarian cancer patients as Lifyorli.
- Recordati: European specialty pharma with a rare endocrine and rare disease portfolio; comparable commercial model targeting endocrinology specialists for niche indications.
Direct peers
- Crinetics Pharmaceuticals: Clinical-stage endocrine-focused biotech developing paltusotine for acromegaly and Cushing's syndrome. Competes directly with Corcept's cortisol/glucocorticoid receptor franchise in hypercortisolism.
- ImmunoGen: Developer of Elahere (mirvetuximab soravtansine), an ADC approved for platinum-resistant ovarian cancer; competes head-to-head with Lifyorli + nab-paclitaxel in the same indication and patient population.
Emerging players
- Sparrow Pharmaceuticals: Private biotech developing SPI-62, a selective HSD-11β1 inhibitor targeting cortisol-driven diseases. Direct overlap with Corcept's Cushing's syndrome and cardiometabolic positioning.
- Clovis Oncology: Oncology company historically focused on ovarian cancer with Rubraca; provides a comparable commercial and clinical profile in the platinum-resistant ovarian cancer segment where Lifyorli launches.
- BridgeBio Pharma: Mid-cap biotech with rare endocrine and cardiometabolic programs (e.g., acromegaly assets); comparable specialty commercial model and overlapping specialist prescriber base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Corcept Therapeutics social profiles
Digital presenceCorcept Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Corcept Therapeutics leadership team
Management profileNumber of profiles
Profiles17 records
Corcept Therapeutics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Corcept Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Corcept Therapeutics
What does Corcept Therapeutics do?
Corcept Therapeutics discovers, develops, and commercializes FDA-approved drugs that regulate the effects of cortisol by modulating the glucocorticoid receptor (GR). The company sells two approved drugs: Korlym (mifepristone), the first FDA-approved treatment for hypercortisolism (Cushing's syndrome) approved in 2012, and Lifyorli (relacorilant), the first selective glucocorticoid receptor antagonist approved (March 2026) for platinum-resistant ovarian cancer in combination with nab-paclitaxel.
Is Corcept Therapeutics a public or private company?
Corcept Therapeutics is a public company. It is classified as public and is currently operating.
When was Corcept Therapeutics founded?
Corcept Therapeutics was founded in 1999. It employs 251 to 500 people.
Where is Corcept Therapeutics based?
Corcept Therapeutics is headquartered in Menlo Park, United States, in the North America region.
How does Corcept Therapeutics make money?
Two revenue lines are on record. Product Sales (Korlym and Lifyorli) is the primary driver. The others are revenue from Cushing's Syndrome Franchise.
Who are Corcept Therapeutics's main competitors?
Broad incumbents on record are Pfizer, Ipsen, Novartis, AstraZeneca and Recordati. Direct peers are Crinetics Pharmaceuticals and ImmunoGen. Emerging players are Sparrow Pharmaceuticals, Clovis Oncology and BridgeBio Pharma.
Does Corcept Therapeutics have an API?
No public API is recorded for Corcept Therapeutics.
What industry is Corcept Therapeutics in?
Corcept Therapeutics's product category is Endocrinology / Oncology Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAKADAN, Endocrine Hypertension & Neuroendocrine Disorders. Its NAICS code is 3254 and its SIC code is 2834.